<DOC>
	<DOCNO>NCT02418546</DOCNO>
	<brief_summary>This phase II feasibility , safety , tolerability preliminary efficacy study e-Health application versus in-person nutritional counseling maintain increase weight patient neurodegenerative disease include amyotrophic lateral sclerosis ( ALS ) , Parkinson 's Disease ( PD ) Huntington 's disease ( HD ) . Primary Objectives include feasibility , safety , tolerability efficacy e-Health application maintain increase body weight compare in-person nutritional counseling . Secondary Objectives measure number calorie require maintain increase body weight neurodegenerative disease stage disease . Tertiary Objectives test effect e-Health application compare in-person nutritional counseling disease progression use ALSFRS-R , UHDRS UDysRS , survival , quality life use PROMIS SF v1.1 scale .</brief_summary>
	<brief_title>Electronic-health Application To Measure Outcomes REmotely Clinical Trial</brief_title>
	<detailed_description>This single center , randomize , open-label , placebo control , parallel group study . The study treatment period approximately 6 month observation period approximately 7 month . There three parallel treatment group : in-person nutritional counseling , nutritional counseling use e-Health App , standard care . Subjects randomly assign 1:1:1 ratio use computer-generated randomization scheme . Subjects two intervention arm give caloric recommendation design cause weight stability modest weight gain , depend current BMI weight loss history . All participant intervention arm receive counsel either in-person remotely App register dietitian ( RD ) work Bionutrition department Clinical Research Center MGH . At MGH , approximately 150 ALS subject ( 50 per treatment group ) enrol . Approximately 75-150 PD HD subject enroll .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<criteria>1 . Adults neurodegenerative disease ALS , PD HD without history unintentional weight loss . 2 . Male female subject age 18 year old . 3 . Participants must capable provide informed consent comply trial procedure . 4 . Participants must MGH swallow screen tool score &gt; 5 time screen visit 5 . Participants designate caregiver must able obtain home weight communicate RD 1 . Clinical evidence unstable medical psychiatric illness , investigator 's judgment , would prevent participant complete assessment . 2 . BMI &gt; 35 combined history cardiovascular disease ; history diabetes regardless BMI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>